Department of Medicine, Cardiovascular Division Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Medicine, Cardiovascular Division Vanderbilt University Medical Center, Nashville, Tennessee.
Heart Rhythm. 2021 Jul;18(7):1153-1161. doi: 10.1016/j.hrthm.2021.02.022. Epub 2021 May 3.
Watchman 2.5 (Boston Scientific Inc, Marlborough, MA) implant success approaches 95% in registries, yet many patients are not attempted because of complex left atrial appendage (LAA) anatomy. Watchman FLX can expand the range of ostium width (14-31.5 mm) and depth available for LAA closure.
The purpose of this study was to evaluate the safety and efficacy of Watchman FLX in patients with a failed Watchman 2.5 attempt or prohibitive LAA anatomy.
The roll-in (n = 58) and primary effectiveness (n = 400) cohorts of the PINNACLE FLX trial comprised the study population. Subjects were identified who previously failed implantation of Watchman 2.5 (n = 11) or were not attempted because of prohibitive LAA anatomy (n = 88). Demographic characteristics, implant procedure details, and TEE follow-up data were compared to controls composed of enrollees not meeting these criteria (n = 359).
Watchman FLX LAA closure was successfully implanted in all subjects with a prior failed Watchman 2.5 attempt (n = 11 of 11). Subjects with previously failed Watchman 2.5 were more likely to receive a 35 mm FLX device than controls (27.3% vs 7.3%; P = .047). Patients with prohibitive anatomy had smaller LAA dimensions than did controls (diameter 18.0 ± 4 mm vs 20.4 ± 3 mm; P < .001 and length 23.7 ± 5 mm vs 28.9 ± 5 mm; P < .001). There was no difference in age, sex, CHADS-VASc score, HAS-BLED score, or primary efficacy between cohorts. Transesophageal echocardiography (TEE) at 12 months showed zero leak in 90.9% in the failed Watchman 2.5 cohort, 91.3% in the prohibitive anatomy cohort, and 89.5% in the control cohort (P = .84). Overall and cardiovascular mortality was lower in the prohibitive anatomy cohort (1.2% vs 8.8% in controls; P = .02).
Watchman FLX implantation in patients with a prior failed Watchman 2.5 attempt or prohibitive LAA anatomy remained safe and highly effective. The association of reduced overall mortality with smaller LAA dimension warrants future study.
Watchman 2.5(波士顿科学公司,马萨诸塞州马尔伯勒)在注册研究中的植入成功率接近 95%,但由于左心耳(LAA)解剖结构复杂,许多患者未被尝试。Watchman FLX 可扩大 LAA 关闭可用的开口宽度(14-31.5 毫米)和深度。
本研究旨在评估 Watchman FLX 在 Watchman 2.5 植入失败或 LAA 解剖结构禁忌的患者中的安全性和有效性。
PINNACLE FLX 试验的滚动入组(n=58)和主要有效性(n=400)队列构成了研究人群。确定了先前植入 Watchman 2.5 失败(n=11)或由于 LAA 解剖结构禁忌而未尝试植入(n=88)的受试者。比较了这些符合这些标准的受试者(n=359)与对照组的人口统计学特征、植入程序细节和 TEE 随访数据。
所有先前 Watchman 2.5 植入失败的患者(n=11 例中的 11 例)均成功植入 Watchman FLX LAA 封堵器。先前 Watchman 2.5 植入失败的患者比对照组更有可能接受 35 毫米 FLX 装置(27.3%对 7.3%;P=0.047)。具有禁忌解剖结构的患者的 LAA 尺寸小于对照组(直径 18.0±4 毫米对 20.4±3 毫米;P<.001 和长度 23.7±5 毫米对 28.9±5 毫米;P<.001)。两个队列在年龄、性别、CHADS-VASc 评分、HAS-BLED 评分或主要疗效方面无差异。12 个月时的经食管超声心动图(TEE)显示,在 Watchman 2.5 植入失败队列中,零漏诊率为 90.9%,在禁忌解剖结构队列中为 91.3%,在对照组中为 89.5%(P=0.84)。禁忌解剖结构队列的总体和心血管死亡率较低(8.8%对对照组中的 1.2%;P=0.02)。
在先前 Watchman 2.5 植入失败或 LAA 解剖结构禁忌的患者中植入 Watchman FLX 仍然是安全且有效的。LAA 尺寸较小与总死亡率降低相关,值得进一步研究。